论文部分内容阅读
从１２例原发性肝细胞癌手术切除实体瘤进行体外分离和培养，获得浸润淋巴细胞（ＴＩＬ）。并对其体外抗肿瘤作用进行测定，其中１０例肝癌患者接受了ＴＩＬ回输免疫治疗。手术前及ＴＩＬ回输后分别检测患者血Ｔ淋巴细胞亚群，可溶性白介素－２受体以观察患者体内免疫机能的变化。结果表明：经ＴＩＬ回输后ＣＤ４，ＣＤ４／ＣＤ８升高明显，ＳＩＬ－２水平明显下降。大部分患者症状明显改善，免疫功能增强，无其它明显副作用
From 12 cases of primary hepatocellular carcinoma, solid tumors were surgically removed and cultured in vitro to obtain infiltrating lymphocytes (TIL). And its anti-tumor effect was measured in vitro, of which 10 cases of liver cancer patients received TIL immunotherapy. Before operation and after TIL reinfusion, blood T-lymphocyte subsets and soluble interleukin-2 receptors were measured to observe the changes of immune function in patients. The results showed that after transfusion of TIL, the levels of CD4 and CD4/CD8 increased significantly, and the level of SIL-2 decreased significantly. Significant improvement in symptoms in most patients, enhanced immune function, no other significant side effects